110 related articles for article (PubMed ID: 28987791)
21. Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer.
Chinnappa P; Taguba L; Arciaga R; Faiman C; Siperstein A; Mehta AE; Reddy SK; Nasr C; Gupta MK
J Clin Endocrinol Metab; 2004 Aug; 89(8):3705-9. PubMed ID: 15292293
[TBL] [Abstract][Full Text] [Related]
22. Serum thyroglobulin in the monitoring of differentiated thyroid cancer.
Evans C; Tennant S; Perros P
Scand J Clin Lab Invest Suppl; 2016; 245():S119-23. PubMed ID: 27542000
[TBL] [Abstract][Full Text] [Related]
23. A high-sensitivity enzyme-linked immunosorbent assay for serum thyroglobulin.
Wunderlich G; Zöphel K; Crook L; Smith S; Smith BR; Franke WG
Thyroid; 2001 Sep; 11(9):819-24. PubMed ID: 11575850
[TBL] [Abstract][Full Text] [Related]
24. [Diagnostic accuracy of 18F-FDG PET in residual or recurrent differentiated thyroid carcinoma with high thyroglobulin and negative 131-I whole-body scan].
Cabrera Martín MN; Pasamontes Pingarrón JA; Carreras Delgado JL; Lapeña Gutiérrez L; Delgado Bolton RC; Bittini Copano A; Pérez Castejón MJ; Fernández Pérez C
Rev Esp Med Nucl; 2007; 26(5):263-9. PubMed ID: 17910834
[TBL] [Abstract][Full Text] [Related]
25. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer.
Esteva D; Muros MA; Llamas-Elvira JM; Jiménez Alonso J; Villar JM; López de la Torre M; Muros T
Ann Surg Oncol; 2009 Jul; 16(7):2006-13. PubMed ID: 19415387
[TBL] [Abstract][Full Text] [Related]
26. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
27. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease.
Saussez S; Glinoer D; Chantrain G; Pattou F; Carnaille B; André S; Gabius HJ; Laurent G
Thyroid; 2008 Jul; 18(7):705-12. PubMed ID: 18630998
[TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer.
Iervasi A; Iervasi G; Ferdeghini M; Solimeo C; Bottoni A; Rossi L; Colato C; Zucchelli GC
Clin Endocrinol (Oxf); 2007 Sep; 67(3):434-41. PubMed ID: 17555505
[TBL] [Abstract][Full Text] [Related]
29. Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.
Pitoia F; Abelleira E; Cross G
Endocrine; 2017 Jan; 55(1):200-208. PubMed ID: 27655291
[TBL] [Abstract][Full Text] [Related]
30. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients.
Duren M; Siperstein AE; Shen W; Duh QY; Morita E; Clark OH
Surgery; 1999 Jul; 126(1):13-9. PubMed ID: 10418587
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of efficacy of various methods of thyroglobulin measurements in differentiated thyroid cancer].
Czernik E; Deja R; Gubała E; Kukulska A; Turska M; Dabrowska-Czuba E; Bartnikowa W; Jarzab B
Wiad Lek; 2001; 54 Suppl 1():339-48. PubMed ID: 12182046
[TBL] [Abstract][Full Text] [Related]
32. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
[TBL] [Abstract][Full Text] [Related]
33. Thyroglobulin: a specific serum marker for the management of thyroid carcinoma.
Whitley RJ; Ain KB
Clin Lab Med; 2004 Mar; 24(1):29-47. PubMed ID: 15157556
[TBL] [Abstract][Full Text] [Related]
34. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer.
Toubeau M; Touzery C; Arveux P; Chaplain G; Vaillant G; Berriolo A; Riedinger JM; Boichot C; Cochet A; Brunotte F
J Nucl Med; 2004 Jun; 45(6):988-94. PubMed ID: 15181134
[TBL] [Abstract][Full Text] [Related]
35. Is a second recombinant human thyrotropin stimulation test useful? The value of postsurgical undetectable stimulated thyroglobulin level at the time of remnant ablation on clinical outcome.
Prior-Sánchez I; Barrera Martín A; Moreno Ortega E; Vallejo Casas JA; Gálvez Moreno MÁ
Clin Endocrinol (Oxf); 2017 Jan; 86(1):97-107. PubMed ID: 27327536
[TBL] [Abstract][Full Text] [Related]
36. Clinical Significance of Serum Interleukin-31 and Interleukin-33 Levels in Patients of Endometrial Cancer: A Case Control Study.
Zeng X; Zhang Z; Gao QQ; Wang YY; Yu XZ; Zhou B; Xi MR
Dis Markers; 2016; 2016():9262919. PubMed ID: 27340318
[TBL] [Abstract][Full Text] [Related]
37. Ablative free thyroxine to thyroglobulin ratio as a predictor of differentiated thyroid cancer recurrence.
Aron M; Cote V; Tamilia M; Hier M; Black MJ; Zhang X; Payne RJ
J Otolaryngol Head Neck Surg; 2009 Oct; 38(5):552-8. PubMed ID: 19769825
[TBL] [Abstract][Full Text] [Related]
38. [Clinical significance of three-week thyroglobulin test in patients with thyroid cancer undergoing thyroidectomy].
Vasil'ev DA; Poroshina TE; Radzhabova ZA; Bershteĭn LM
Vopr Onkol; 2012; 58(4):481-5. PubMed ID: 23607201
[TBL] [Abstract][Full Text] [Related]
39. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.
Baudin E; Do Cao C; Cailleux AF; Leboulleux S; Travagli JP; Schlumberger M
J Clin Endocrinol Metab; 2003 Mar; 88(3):1107-11. PubMed ID: 12629092
[TBL] [Abstract][Full Text] [Related]
40. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
Kim TY; Kim WB; Kim ES; Ryu JS; Yeo JS; Kim SC; Hong SJ; Shong YK
J Clin Endocrinol Metab; 2005 Mar; 90(3):1440-5. PubMed ID: 15613412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
